Featured
Featured
Featured
Insights & Resources
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
A fairness opinion is a form of valuation analysis, which differs from other valuation analyses in that it evaluates the value received in the transaction in addition to the value exchanged.
Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.
Tyler Ridley joined this episode of Weaver: Beyond the Numbers podcast with Weaver hosts Howard Altshuler and Rob Nowak to discuss the rebound and current financial state of the biopharma and med tech industries.